

# Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Jeff P. Sharman, MD; Talha Munir, PhD, MBBS; Sebastian Grosicki, MD, PhD; Lindsey E. Roeker, MD; John M. Burke, MD; Christine I. Chen, MHPE, MD; Norbert Grzasko, MD, PhD; George Follows, PhD, MA, BM, BCh, FRCP; Zoltán Mátrai, MD, PhD; Alessandro Sanna, MD; Luguí Qiu, MD; Ru Feng, MD; Vu Minh Hua, PhD, MBBS, FRACP, FRCPA; Wojciech Jurczak, MD, PhD; Matthias Ritgen, MD; Shuhua Yi, MD; Francesc Bosch, MD, PhD; Catherine C. Coombs, MD; Katherine Bao, PhD; Vishalkumar Patel, MD; Bin Liu, MSc, MPH; Livia Compte, MD, PhD; Ananya Guntur, PhD; Denise Y. Wang, PhD; Marisa Hill, MS, MD; Ching Ching Leow, PhD; Paolo Ghia, MD, PhD; and Paul M. Barr, MD

The article by Sharman et al entitled “Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)” (*Journal of Clinical Oncology* 10.1200/JCO-25-00166) was published online June 06, 2025, with errors.

Figure A2, Forest plot of TTNT, was duplicated for Figure A1, Forest plot of IRC-assessed PFS.

This has been corrected as of July 29, 2025. We apologize for the errors.

DOI: <https://doi.org/10.1200/JCO-25-01700>